Evidence map›Paper›PMID 29338678›Full record

SynthesisCurrent neuropharmacology2019

Supplementation with Curcuma longa Reverses Neurotoxic and Behavioral Damage in Models of Alzheimer's Disease: A Systematic Review.

Ianara Mendonça da Costa, Marco Aurelio de Moura Freire, José Rodolfo Lopes de Paiva Cavalcanti, Dayane Pessoa de Araújo, Bianca Norrara, Isleânia Maria Marques Moreira Rosa, Eduardo Pereira de Azevedo, Amália Cinthia Meneses do Rego, Irami Araújo Filho, Fausto Pierdoná Guzen

Open access · bronzeAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Current neuropharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 6 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 6 syntheses or guidelines pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Review
  8. Article
  9. Neuroprotective and anti-inflammatory activity ofFrontiers in pharmacology · 2025
    Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Influence of CurQfenFrontiers in dementia · 2023
    Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Ianara Mendonça da CostaLaboratory of Experimental Neurology, Department of Biomedical Sciences, Faculty of Health Sciences, University of the State of Rio Grande do Norte, Mossoro/RN, Brazil.
Marco Aurelio de Moura FreireLaboratory of Experimental Neurology, Department of Biomedical Sciences, Faculty of Health Sciences, University of the State of Rio Grande do Norte, Mossoro/RN, Brazil.
José Rodolfo Lopes de Paiva CavalcantiLaboratory of Experimental Neurology, Department of Biomedical Sciences, Faculty of Health Sciences, University of the State of Rio Grande do Norte, Mossoro/RN, Brazil.
Dayane Pessoa de AraújoLaboratory of Experimental Neurology, Department of Biomedical Sciences, Faculty of Health Sciences, University of the State of Rio Grande do Norte, Mossoro/RN, Brazil.
Bianca NorraraLaboratory of Experimental Neurology, Department of Biomedical Sciences, Faculty of Health Sciences, University of the State of Rio Grande do Norte, Mossoro/RN, Brazil.
Isleânia Maria Marques Moreira RosaLaboratory of Experimental Neurology, Department of Biomedical Sciences, Faculty of Health Sciences, University of the State of Rio Grande do Norte, Mossoro/RN, Brazil.
Eduardo Pereira de AzevedoPost Graduation Program in Biotechnology, Health School, Potiguar University (UnP), Natal/RN, Brazil.
Amália Cinthia Meneses do RegoPost Graduation Program in Biotechnology, Health School, Potiguar University (UnP), Natal/RN, Brazil.
Irami Araújo FilhoPost Graduation Program in Biotechnology, Health School, Potiguar University (UnP), Natal/RN, Brazil.
Fausto Pierdoná GuzenLaboratory of Experimental Neurology, Department of Biomedical Sciences, Faculty of Health Sciences, University of the State of Rio Grande do Norte, Mossoro/RN, Brazil.
Universidade do Estado do Rio Grande do Norte · BRUniversidade Potiguar · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe formation of senile plaques and neurofibrillary tangles of the tau protein are the main pathological mechanism of Alzheimer's disease (AD). Current therapies for AD offer discrete benefits to the clinical symptoms and do not prevent the continuing degeneration of neuronal cells. Therefore, novel therapeutic strategies have long been investigated, where curcumin (Curcuma longa) has shown some properties that can prevent the deleterious processes involved in neurodegenerative diseases.

objectiveThe aim of the present work is to review studies that addressed the effects of curcumin in experimental models (in vivo and in vitro) for AD.

methodThis study is a systematic review conducted between January and June 2017, in which a consultation of scientific articles from indexed periodicals was carried out in Science Direct, United States National Library of Medicine (PubMed), Cochrane Library and Scielo databases, using the following descriptors: "Curcuma longa", "Curcumin" and "Alzheimer's disease".

resultsA total of 32 studies were analyzed, which indicated that curcumin supplementation reverses neurotoxic and behavioral damages in both in vivo and in vitro models of AD.

conclusionThe administration of curcumin in experimental models seems to be a promising approach in AD, even though it is suggested that additional studies must be conducted using distinct doses and through other routes of administration.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAnimalsCurcumaCurcuminDietary SupplementsHumansNeurofibrillary TanglesNeuroprotective AgentsPlant ExtractsRandomized Controlled Trials as TopicAmyloid beta-PeptidesCurcuminNeuroprotective AgentsPlant Extractsturmeric extractAlzheimer's diseaseAβ aggregationbraincurcuminoxidative stresstherapeutics.

Identifiers

PMID29338678
PMCPMC6520588
OpenAlexW2783022032

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.